entertainment -WSS

entertainment

author：leisure time 2025-09-27 09:54:06 - browse：3472

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Flu, Covid vaccination rates decline, new survey data show

WSS

Anavex keeps shifting the goalposts in its clinical trials

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

What will Novo Nordisk's VC do with its influx of cash?

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Wegovy’s successful heart trial raises vital question about weight loss

Will an HIV vaccine ever be a reality?

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Hollywood unions extend contract negotiations for actors

European officials brace for rough respiratory virus season

Walensky prepares to leave CDC — and Congress — behind

What we owe ALS patients — and why one company fell short

Heart attack and stroke risk calculators need revising

Friends ask where James Watson's attitudes about race came from

At least 13 dead in Texas as scorching temps continue

With Roe v Wade overturned, abortion providers work to adapt

Moonlake's readout produced a cash windfall. Risks remain

The best solution to the drug shortages problem

focus

New oral drug delivery patch is modeled after octopus tentacles

FDA panel issues narrow recommendation for Covid vaccine booster doses

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Medicare innovation center doesn’t save money, experts say

NIH trials fail to test meaningful long Covid therapies, experts say

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Wikipedia

leisure time

leisure time

knowledge